欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

休市中 10-30 16:08:08

4.790

+0.180

+3.90%

最高5.000	最低4.665	成交量12.00万
今开4.990	昨收4.610	日振幅7.27%
总市值39.04亿	流通市值39.04亿	总股本8.15亿
成交额57.41万	换手率0.01%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":4.79,"timestamp":1793347688005,"preClose":4.61,"halted":0,"volume":120000,"delay":0,"changeRate":0.03904555314533616,"floatShares":815000000,"shares":815000000,"eps":-0.23591984684910872,"marketStatus":"休市中","change":0.18,"latestTime":"10-30 16:08:08","open":4.99,"high":5,"low":4.665,"amount":574115,"amplitude":0.072668,"askPrice":4.79,"askSize":4500,"bidPrice":4.69,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.18636960141539038,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":4.61,"openAndCloseTimeList":[[1793323800000,1793332800000],[1793336400000,1793347200000]],"volumeRatio":0.204430624892407,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2680427230","title":"泽璟制药（688266）2026年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2680427230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680427230?lang=zh_cn&edition=full","pubTime":"2026-11-01 06:27","pubTimestamp":1793485648,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泽璟制药发布2026年三季报。截至本报告期末，公司营业总收入15.36亿元，同比上升158.91%，归母净利润6.38亿元，同比上升783.25%。本报告期泽璟制药盈利能力上升，毛利率同比增幅2.92%，净利率同比增幅357.87%。本文数据来源于泽璟制药2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110100001481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679180452","title":"汇宇制药(688553)9月30日股东户数1.94万户，较上期增加17.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679180452","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679180452?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:13","pubTimestamp":1793358836,"startTime":"0","endTime":"0","summary":"证券之星消息，近日汇宇制药披露，截至2026年9月30日公司股东户数为1.94万户，较6月30日增加2929.0户，增幅为17.74%。在化学制药行业个股中，汇宇制药股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.98万户。从股价来看，2026年6月30日至2026年9月30日，汇宇制药区间涨幅为20.88%，在此期间股东户数增加2929.0户，增幅为17.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK1191","BK1574","BK0239","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679429021","title":"再生元制药(REGN.US)Q3业绩超预期 上调全年净产品毛利率指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2679429021","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679429021?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:58","pubTimestamp":1793357928,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再生元制药发布 2026 年第三季度业绩：总营收 51.158 亿美元，同比增长 36.3%，高于 IBES 一致预期的 45.42 亿美元;GAAP 摊薄每股收益 18.45 美元、同比增 35.5%。非 GAAP 摊薄每股收益 20.07 美元、同比增 69.7%，较 IBES 预期的 16.20 美元高出约 24%。公司上调 2026 年净产品毛利率指引至约 80%，同时下调销售及管理费用与资本开支指引。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU1917777945.USD","LU2023250504.SGD","IBBQ","LU2237438978.USD","BK4588","LU2362541513.USD","LU2468319806.SGD","LU0823416689.USD","LU2362541273.HKD","REGN","01477","BBH","LU0114720955.EUR","LU2362540622.SGD","BK4585","IBB","LU1974910355.USD","LU2106854487.HKD","LU0109394709.USD","LU0823434583.USD","LU0320765992.SGD","LU0289739699.SGD","LU2089984988.USD","BK4139","LU0882574055.USD","LU0053666078.USD","LU0058720904.USD","LU0823434740.USD","BK1574","LU0889565916.HKD","TBXU","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679297067","title":"图解汇宇制药三季报：第三季度单季净利润同比增长52.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679297067","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679297067?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:40","pubTimestamp":1793356804,"startTime":"0","endTime":"0","summary":"证券之星消息，汇宇制药2026年三季报显示，前三季度公司主营收入8.66亿元，同比上升16.71%；归母净利润1.03亿元，同比上升303.36%；扣非净利润1.34亿元，同比上升68.59%；其中2026年第三季度，公司单季度主营收入3.14亿元，同比上升8.74%；单季度归母净利润4567.01万元，同比上升52.66%；单季度扣非净利润5603.59万元，同比上升77.96%；负债率27.82%，投资收益-770.51万元，财务费用-5114.94万元，毛利率76.4%。财报数据概要请见下图:本文数据来源于汇宇制药2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000044587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679291138","title":"歌礼制药-B(01672.HK)10月30日耗资约150.02万港元回购30万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679291138","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679291138?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:54","pubTimestamp":1793354064,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01672","BK1161","01477","BK1574","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679966312","title":"汇宇制药(688553.SH)发布前三季度业绩，归母净利润1.03亿元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2679966312","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679966312?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:15","pubTimestamp":1793351745,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药(688553.SH)披露2026年第三季度报告，前三季度公司实现营业收入8.66亿元，同比增长16.71%;归母净利润1.03亿元，同比扭亏为盈;扣非净利润1.34亿元，同比增长68.59%;基本每股收益0.17元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679472738","title":"只有一个人的制药公司，被Anthropic在IPO前收购了","url":"https://stock-news.laohu8.com/highlight/detail?id=2679472738","media":"字母榜","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679472738?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:50","pubTimestamp":1793267457,"startTime":"0","endTime":"0","summary":"Anthropic昨天公布了一笔特殊的交易：今年7月，它收购了一家名为Mithril Medicine的生物医药初创公司。01只有一个人的制药公司，被Anthropic看中Anthropic没有公布这笔收购的金额，但明确表示，Mithril Medicine的两条药物研发管线，已经成为公司首批内部药物研发项目。也就是说，Anthropic正在亲自参与新药研发，而这次被它收购的公司，只有一个全职员工。直到被Anthropic收购，他才决定主动揭晓身份。今年1月，Anthropic又将产品扩展到临床试验管理、药品监管等环节。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8xbrHxmwD27","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK1191","BK4127","KCE","REDS","BK1574","FRHC","ANT","01477","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679799514","title":"歌礼制药-B(01672)10月29日耗资约52.54万港元回购10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679799514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679799514?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:35","pubTimestamp":1793266559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，2026年10月29日耗资约52.54万港元回购10万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","BK1574","01477","BK1191","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679479959","title":"歌礼制药-B(01672.HK)10月29日耗资约52.54万港元回购10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679479959","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679479959?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:35","pubTimestamp":1793266559,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1574","BK1191","BK1161","01477","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679473495","title":"10月29日泽璟制药跌6.43%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679473495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679473495?lang=zh_cn&edition=full","pubTime":"2026-10-29 16:47","pubTimestamp":1793263678,"startTime":"0","endTime":"0","summary":"证券之星消息，10月29日泽璟制药跌6.43%创60日新低，收盘报84.2元，换手率2.37%，成交量6.28万手，成交额5.35亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共75家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900040733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","09939","BK1574","BK1191","01477","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679344602","title":"泽璟制药（688266）10月28日主力资金净卖出1567.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679344602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679344602?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:46","pubTimestamp":1793234808,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月28日收盘，泽璟制药报收于89.99元，下跌4.27%，换手率2.31%，成交量6.13万手，成交额5.56亿元。近5日资金流向一览见下表：泽璟制药融资融券信息显示，融资方面，当日融资买入2399.24万元，融资偿还1412.79万元，融资净买入986.45万元。泽璟制药主营业务：化学新药及生物新药的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900015136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239","BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679445200","title":"国金证券：AI制药有望显著压缩研发周期与开支","url":"https://stock-news.laohu8.com/highlight/detail?id=2679445200","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679445200?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:19","pubTimestamp":1793233199,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["ARTY","AIPO","BK0183","BK0201","BK1574","AGIX","600109","BK0012","01477","BK0276","BK0028","VTHR","BK1191","BK0188","QTOC","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679544598","title":"歌礼制药：ASC30治疗2型糖尿病的美国II期研究取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2679544598","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679544598?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:04","pubTimestamp":1793232290,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","BK1515","01672","BK1574","BK1161","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679443709","title":"歌礼制药-B(01672)：GLP-1口服小分子ASC30在糖尿病受试者中进行的美国II期研究第12周时实现经安慰剂校正后的糖化血红蛋白(HbA1c)下降达1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679443709","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679443709?lang=zh_cn&edition=full","pubTime":"2026-10-29 07:42","pubTimestamp":1793230934,"startTime":"0","endTime":"0","summary":"主要终点是第12周时糖化血红蛋白相较基线的下降;次要终点之一是第13周时体重相较基线的下降。主要终点方面，与安慰剂相比，ASC30在糖尿病受试者中实现了具有统计学显著性和临床意义的糖化血红蛋白下降。受试者基线平均糖化血红蛋白为8.3%。糖尿病受试者中观察到的良好胃肠道耐受性与在肥胖或超重受试者中进行的研究中的发现一致。就所有其他安全性信号而言，ASC30在糖尿病受试者中展现出良好的安全性特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["JDOC","BK1161","BK1515","BK1191","01672","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678493386","title":"三季度扣非净利润环比增长857.75%，华兰股份业绩与AI制药布局齐头并进","url":"https://stock-news.laohu8.com/highlight/detail?id=2678493386","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678493386?lang=zh_cn&edition=full","pubTime":"2026-10-28 20:38","pubTimestamp":1793191080,"startTime":"0","endTime":"0","summary":"2026年10月28日晚间，华兰股份(301093)发布2026年第三季度报告。第三季度，公司实现营业收入1.62亿元，同比增长22.40%；归属于上市公司股东的净利润2453.85万元，同比增长156.04%；扣除非经常性损益后的归母净利润1981.48万元，同比增长229.91%；基本每股收益为0.1152元，同比增长154.87%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202610283912444897.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610283912444897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["AGIX","VTHR","QTOC","301093","AIPO","CHAT","ARTY","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678955450","title":"Anthropic收购小型制药初创企业，深度布局生物技术领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2678955450","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678955450?lang=zh_cn&edition=full","pubTime":"2026-10-28 17:51","pubTimestamp":1793181060,"startTime":"0","endTime":"0","summary":"Anthropic 宣布收购 Mithril Medicine。此举标志这家 AI 公司在药物研发领域的野心持续扩张。Anthropic 同时披露，公司正与百时美施贵宝、BigHat Biosciences 以及另外四家机构合作，将 Claude 大模型应用于抗体设计、临床试验规划等各类工作。本次收购交易的具体条款，Anthropic 并未对外披露。在周一提交的 IPO 申报文件当中，Anthropic 将 “借助 AI 发掘全新疾病治疗方案” 列为对人类最具价值的应用方向之首。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-28/doc-iniwuqvs6543672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1574","WDNA","01477","HELX","ANT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678468910","title":"19个项目18个成功，6个GPCR靶点全获命中！国产AI制药再破技术天花板","url":"https://stock-news.laohu8.com/highlight/detail?id=2678468910","media":"量子位","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678468910?lang=zh_cn&edition=full","pubTime":"2026-10-28 13:24","pubTimestamp":1793165068,"startTime":"0","endTime":"0","summary":"19个项目18个获得可结合分子，项目成功率达94.7%，全部453个受测候选中，139个获得确认结合，整体候选命中率30.7%。报告显示，MMDesign针对CCR7、CCR8、EP2、GPR68、NK3R、A2AR六个GPCR靶点开展从头设计，全部成功获得实验确认的结合分子。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8xaMcSLMa0V","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["CHAT","GPCR","AGIX","AIPO","BK1574","BK1191","BK4007","QTOC","01477","BK4599","ARTY","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678431538","title":"Anthropic全面杀入AI制药！收购“一人药企”，联手6大巨头，最新研发进度曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2678431538","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678431538?lang=zh_cn&edition=full","pubTime":"2026-10-28 11:25","pubTimestamp":1793157954,"startTime":"0","endTime":"0","summary":"Anthropic收购单人生物科技公司Mithril Medicine，18个月内将罕见肌肉萎缩症候选疗法推至小鼠实验并获初步积极结果；同步与BMS、Generate Biomedicines等六大机构深度合作，Claude在分子设计、临床规划等环节均取得可量化进展，最快2028年底或启动人体临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3784640","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHAT","QTOC","AGIX","ARTY","01477","BK1191","AIPO","VTHR","BK1574","ANT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678243653","title":"创新药概念板块走强 恒瑞医药（01276）涨超11% 券商看好ADC、双抗等出海赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2678243653","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678243653?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:32","pubTimestamp":1793154754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念板块走强，截至发稿，恒瑞医药 涨11.14%，金斯瑞生物涨9.39%，康方生物涨4.70%，诺诚健华涨3.50%，欧康维视生物-B涨3.33%，亚盛医药涨2.65%，翰森制药涨2.32%。2026年，继续看好中国创新药出海的产业趋势，继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994616","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","BK0196","09926","LU0405327148.USD","BK0188","BK1191","06855","LU0359201885.HKD","LNGR","01548","BK1576","HK0000320264.USD","LU0634319403.HKD","LU1961090484.USD","LU0348827113.USD","BK0183","LU1655091616.SGD","BK1589","06978","03692","KCE","LU0417516571.SGD","LU0348735423.USD","LU2328871848.SGD","MEDX","LU2097828474.EUR","KURE","LU1997245177.USD","LU1820825898.SGD","LU2476274720.SGD","IE00B543WZ88.USD","LU2289578879.USD","09969","LU2778985437.USD","IBBQ","LU0348767384.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0417516738.SGD","LU0359201612.USD","LU1720050803.USD","600276","BK1161","LU1064130708.USD","LU0348783233.USD","01477","LU1781817850.SGD","159992","LU1328615791.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678433290","title":"东北证券：研发提效需求驱动 AI制药加速产业落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2678433290","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678433290?lang=zh_cn&edition=full","pubTime":"2026-10-28 09:48","pubTimestamp":1793152089,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东北证券发布研究报告称，聚焦成果转化，把握商业验证与临床验证两条主线。市场空间：研发提效需求明确，AI相关投入加速增长根据弗若斯特沙利文报告，全球药物研发支出预计由2023年的2,605亿美元增至2030年的3,943亿美元，年复合增长率为6.1%;全球AI赋能药物研发支出由2023年的119亿美元增至2032年的746亿美元，年复合增长率约22.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","AGIX","VTHR","BK0028","BK1574","QTOC","000686","CHAT","01477","ARTY","BK0183","BK0188","BK0276","AIPO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":0.0527},{"period":"1month","weight":-0.058},{"period":"3month","weight":-0.0534},{"period":"6month","weight":-0.3527},{"period":"1year","weight":-0.396},{"period":"ytd","weight":-0.3527}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.0536},{"period":"3month","weight":-0.1001},{"period":"6month","weight":-0.0963},{"period":"1year","weight":-0.1137},{"period":"ytd","weight":-0.0911}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.087204},{"month":6,"riseRate":0.666667,"avgChangeRate":0.062947},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003589},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.052517},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.073222},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.112188},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}